Drug Type Monoclonal antibody |
Synonyms SRK 256, SRK256 |
Target |
Mechanism HJV inhibitors(Hemochromatosis type 2 protein inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Anemia, Iron-Deficiency | Preclinical | US | 11 Dec 2023 |